US panel endorses Schering-Plough's antipsychotic asenapine
This article was originally published in Scrip
Executive Summary
Schering-Plough's investigational atypical antipsychotic Saphris (asenapine maleate) sublingual tablet is safe and effective for the acute treatment of schizophrenia and manic or mixed episodes of bipolar I disorder, the US FDA's outside experts said.